On January 14, 2021 Lantern Pharma (Nasdaq: LTRN), a clinical-stage biopharma company using its proprietary RADR artificial intelligence ("A.I.") platform to transform cancer drug development and identify patients who will benefit from its targeted oncology therapeutics, reported the pricing of a public offering of 4,285,715 shares of its common stock at a public offering price of $14.00 per share, for gross proceeds of $60 million, before deducting underwriting discounts and offering expenses (Press release, Lantern Pharma, JAN 14, 2021, View Source [SID1234574056]). In addition, Lantern Pharma has granted the underwriters a 45-day option to purchase up to an additional 642,856 shares of common stock at the public offering price, less the underwriting discount, to cover over-allotments. All of the shares of common stock are being offered by Lantern Pharma.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The offering is expected to close on January 20, 2021, subject to satisfaction of customary closing conditions.
ThinkEquity, a division of Fordham Financial Management, Inc., is acting as sole book-running manager for the offering. Colliers Securities LLC is acting as co-manager for the offering.
A registration statement on Form S-1 (File No. 333-251992) relating to the shares was filed with the Securities and Exchange Commission ("SEC") and became effective on January 14, 2021. This offering is being made only by means of a prospectus. Copies of the final prospectus, when available, may be obtained from ThinkEquity, a division of Fordham Financial Management, Inc., 17 State Street, 22nd Floor, New York, New York 10004, by telephone at (877) 436-3673, by email at [email protected]. The final prospectus will be filed with the SEC and will be available on the SEC’s website located at View Source
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.